Upstream & Downstream Processing

MilliporeSigma goes acoustic with FloDesign Sonics buy

Merck KGaA unit MilliporeSigma has boosted its CAR-T autologous manufacturing services by buying FloDesign Sonics, adding an acoustic cell processing platform. MilliporeSigma, the life sciences division of Germany’s Merck, says it intends to offer the tech platform of its new acquisition to cell therapy manufacturing customers. Massachusetts-based FloDesign Sonics’ first commercial product, Ekko, allows the wash, concentration and formulation is based on its acoustic wave separation (AWS) system that uses a three-dimensional standing wave that traps and gathers cells in…

Glenmark taps CHO cell line from Horizon Discovery

Glenmark Pharmaceuticals says it has integrated Horizon’s GS knockout CHO K1 platform into its cell line portfolio and will use it to develop future monoclonal antibodies. After what Glenmark Pharmaceuticals said was a “stringent evaluation of the cell line,” the drugmaker has licensed Horizon Dscovery’s gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line. According to a Glenmark spokesperson, Horizon’s CHO-based cell line demonstrated consistently impressive performance, with high levels of productivity, favorable stability profile, and transparent…

Eppendorf invests €20m to expand German consumables plant

The Eppendorf Group says the expansion of its site in northern Germany will increase production capacity for life science consumables by around 30%. Construction of two production halls at Eppendorf’s site in Oldenburg in Holstein are set to begin next year in efforts to increase the firm’s laboratory consumables’ volume. Julie Brahms, a spokesperson from the firm, told Bioprocess Insider the expansion represents an investment of about €20 million ($22 million) and – from 2021 when production begins – will…

Peptide A? JSR teams on synthetic affinity chromatography ligands

JSR Corporation has teamed with PeptiDream to develop a synthetic peptide-based affinity chromatography media that could be an alternative to costly Protein A resin. The partnership will combine PeptiDream’s drug discovery platform, PDPS (Peptide Discovery Platform System), with JSR’s knowledge of affinity separation technology to develop affinity chromatography media from unique peptides that bind to various target proteins in a specific manner. A peptide-based resin can be a platform for affinity purification for various types of therapeutic proteins, it could…

Thermo Fisher scaling single-use bioreactors up to 5,000 L

There is increasing demand for large-scale single-use bioreactors says Thermo Fisher as it prepares to launch disposable systems up to 5,000 L in volume. Thermo Fisher Scientific showcased its latest bioprocess offerings at Biotech Week Boston earlier this month. This included an update to its HyPerforma DynaDrive single-use bioreactor (SUB) range, which will see the firm offer biomanufacturers disposable bioreactors with volumes more than doubling its current volume limit. Single-use technologies have been fully adopted by the industry, but most…

Scancell adds first partner for high potent MAb tech

Immuno-oncology firm Scancell has begun offering its AvidiMab technology to partners looking to increase the potency of their monoclonal antibody pipelines. Scancell has its own pipeline of monoclonal antibodies (MAbs) targeting novel cancer treatments, but this deal represents the first collaboration with an external partnerover its AvidiMab technology. “AvidiMab is proprietary technology to enable the modification of the constant region (FC) of a human antibody to allow direct tumor killing of antibodies directed to tumor associated antigens (TaGs) but may…

ABEC breaks plastic ceiling again with 6,000 L single-use bioreactor

ABEC has launched a single-use bioreactor system with a working volume of 6,000 L – three times that of industry’s standard upper limit. While single-use bioreactors are a staple in the industry these days, one of the commonly discussed limitations of such systems in a commercial setting are their size. Most vendors offer bioreactors of 2,000 L as their upper limit leaving biomanufacturers to either run several systems in unison or opt for stainless-steel tanks if requiring larger volumes. But…

MilliporeSigma buys data platform to bolster its Biopharma 4.0 offering

MilliporeSigma has bought the rights to the ProcessPad platform from Simplyfeye Softwares, adding the latest “building block” to its BioContinuum Platform. The ProcessPad platform from Simplyfeye Softwares Private Limited brings MilliporeSigma a data management and analytics solution capable of capturing development, scale-up, commercial and process data on a single platform as well as analyzing quantitative and qualitative batch manufacturing data. Financial details around the acquisition were not disclosed, but Michael Felo, director of Integrated Solutions Marketing, BioContinuum Platform, at MilliporeSigma,…

Introducing Cytiva: GE plans name change ahead of $21bn Danaher buy

GE Healthcare’s Biopharma business has announced plans to change its name and logo in anticipation of its acquisition by Danaher Corporation later this year. “On February 25 our lives changed,” Dodi Axelson, head of Communications, Life Sciences at GE Healthcare told Bioprocess Insider. She spoke, of course, about the agreement by Danaher Corporation to acquire the BioPharma portion of GE Healthcare’s Life Sciences business for a cash price of $21.4 billion (€19.4 billion). The deal is still under regulatory review…

Batavia selects CHO platform for Zika Ab on the Horizon

A collaboration led by Batavia Biosciences will use Horizon Discovery’s CHO cell technology in the development of an antibody against Zika. Batavia Biosciences, working with Vanderbilt University Medical Center (VUMC) and IDBiologics, is looking to develop a therapy based on a Zika virus neutralizing antibody that was discovered three years ago. Accessing Horizon Discovery’s GS knockout Chinese hamster ovary (CHO) K1 cell line expression system will allow the development of high yield antibody-expressing cell lines, Batavia CEO Menzo Havenga told…